Objective: To observe the clinical efficacy and safety of Shengmai Yangxin fang for treating the patients with acute coronary syndrome(ACS) in syndrome of asthenia of qi and blood. Method: Ninety cases of patients with ACS in syndrome of asthenia of qi and blood were randomly divided into treatment group and control group. The all patients were given basic treatment of western

the treatment group was given the treatment of Shengmai Yangxin fang

the control group was given only basic treatment of western. The clinical efficacy was evaluated after a course of treatment. The cardiac function

angina pectoris and frequency of attacks of the two group were compared before treatment and after treatment

the adverse cardiovascular events were recorded during treatment. Result: The effective rate of treatment group was 91.1%

the control group was 53.3%

the difference was significant between the two groups (P <0.01). After treatment the left ventricular ejection fraction(LVEF)

CO and E/A of the two groups increased significantly

compared with the prior-treatment the difference was significant (P <0.05)

and the difference was significant between the two groups (P <0.05). After treatment the angina attack frequency and duration of the two groups were significantly reduced

compared with pre-treatment the difference was significant ( P <0.05)

and the treatment group compared with the control group the difference was significant ( P <0.05). The incidence of adverse events of treatment group was significantly lower than the control group

he difference was significant ( P <0.05). Conclusion: The Shengmai Yangxin fang for treating the patients with ACS in syndrome of asthenia of Qi and Blood is safe and effective.